Full-text resources of CEJSH and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


2013 | 3 | 438-440

Article title

Wykorzystanie Internetu we wczesnym rozpoznawaniu akromegalii


Title variants

Languages of publication






  • Melmed S. Medical progress: acromegaly. N Engl J Med 2006; 355: 2558–2573.
  • Bolanowski M, Schopohl J, Marciniak M, et al. Acromegaly due to GHRH-secreting large bronchial carcinoid. Complete recovery following tumor surgery. Exp Clin Endocrinol Diabet 2002; 110: 188–192.
  • Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999; 2: 29–41.
  • Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management.Endocr Rev 2004; 25: 102–152.
  • Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89:667–674.
  • Bolanowski M, Kałużny M, Jawiarczyk-Przybyłowska A. Somatotropinoma – akromegalia. W: Milewicz A, red. Endokrynologia kliniczna. T. 1. Wrocław: PTE; 2012: 157–162.
  • Schneider HJ, Kosilek RP, Günther M, et al. A novel approach to the detection of acromegaly: accuracy of diagnostic by automatic face classification. J Clin Endocrinol Metab 2011; 96: 2074–2080.
  • Akromegalia.pl – razem w walce z chorobą. www.akromegalia.pl.
  • Rosario PW, Calsolari MR. Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care unit. Pituitary 2012; 15: 179–183.
  • Colao A. The importance of presurgical somatostatin analogue therapy in acromegaly. Endokrynol Pol 2007; 58: 356–360.
  • Bolanowski M, Bar-Andziak E, Kos-Kudła B, et al. Consensus statement of the Polish Society for Endocrinology: presusurgical somatostatin analogs therapy in acromegaly. Neuroendocrinol Lett 2008; 29: 59–62.
  • Colao A, Auriemma RS, Rebora A, et al. Significant tumor shrinkage after 12 months of lanreotide Autogel 120 mg treatment given first-line in acromegaly. Clin Endocrinol 2009; 71: 237–245.
  • van der Lely AJ, Biller BMK, Brue T, et al. Long-term safety of Pegvisomant in patients with acromegaly: comprehensive review of 1288 Subjects in Acrostudy. J Clin Endocrinol Metab 2012; 97: 1589–1597.
  • Jawiarczyk A, Bolanowski M, Kałużny M, et al. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. Neuro Endocrinol Lett 2008; 29: 571–576.
  • Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly:a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010; 95: 2781–2789.
  • Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly – a meta-analysis. J Clin Endocrinol Metab 2011; 96:1327–1335.
  • Higham CE, Atkinson AB, Aylwin S, et al. Combination treatment with Cabergoline and low-dose Pegvisomant in active acromegaly:a prospective clinical trial. J Clin Endocrinol Metab 2012; 97: 1187–1193.

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.